

# Serum soluble alpha-klotho concentrations are not dependent on vitamin D status in maintenance dialysis patients



<sup>1</sup>Sylvie Dusilova Sulkova\*, <sup>2</sup>Marta Kalousova\*,  
<sup>3</sup>Jaroslava Vavrova, <sup>1</sup>Roman ˇSafranek, <sup>4</sup>Eva Vykoukalova,  
<sup>1</sup>Alena Mala, <sup>2</sup>Tomas Zima, <sup>3</sup>Ladislava Pavlikova,  
<sup>3</sup>Vladimir Palicka

\*both authors equally contributed

<sup>1</sup>Haemodialysis Centre, University Hospital Hradec Kralove

<sup>2</sup>Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague

<sup>3</sup>Dept of Clinical Biochemistry and Diagnostics, University Hospital and Faculty of Medicine of Charles University, Hradec Kralove

<sup>4</sup>Centre of Internal Medicine, Regional Hospital of Liberec, Czech Republic

## Introduction

The long extracellular chain of the single-pass transmembrane protein klotho may be released into the blood (soluble klotho). Circulating blood levels of alpha-klotho in haemodialysis (HD) patients are low. Clinical significance of circulating klotho is extensively studied. Vitamin D may increase the klotho gene expression. However, the relation between serum vitamin D concentrations and serum soluble klotho is not known (references 1-6).

## Objective

To determine serum values of novel markers of bone mineral metabolism, including soluble alpha-klotho, before and after correction of vitamin D deficit in maintenance HD patients. Especially, we focused on the relation between soluble klotho and serum vitamin D metabolites (25D and 1,25D).

## Patients and methods

- N = 80 clinically stable maintenance HD patients (50 M; mean age 66 years)
  - low vitamin D status at baseline (serum 25D below 50 nmol/l)
  - supervised administration of cholecalciferol (5000 IU once weekly)
  - laboratory parameters assessed at baseline and after 15 weeks
    - clinical follow-up continued for 36 months (outcome)

Fig. 1: Soluble alpha-klotho (pg/ml; ELISA; IBL, Germany)




Fig. 2: 25D (nmol/l; CLIA; DiaSorin, USA)




Fig. 3: 1,25D (pmol/l; CLIA; DiaSorin, USA)




Fig. 5: Sclerostin (pmol/l; ELISA; Biomedica, Austria)




Fig. 4: Vitamin D binding protein (ug/ml; ELISA; RD System, USA)




Fig. 6: Fetuin A (ug/ml; ELISA; BioVendor, CZ)





Fig. 7: Intact FGF-23 (pg/ml; ELISA; Immunotopics, USA)



## Results

Data are given as median (interquartile range) and are presented in figures.

Fig. 9: Ca (mmol/l; routine analysis; COBAS 8000, Roche, Switzerland)




Fig. 8: iPTH (pmol/l; Immulite; Siemens, USA)




Fig. 11: Beta-cross-laps (ug/l, routine analysis; COBAS 8000, Roche, Switzerland)




Fig. 10: P (mmol/l; routine analysis; COBAS 8000, Roche, Switzerland)





Fig. 12: 25D vs soluble alpha-klotho



## Comments

- Serum 25D increased markedly after vitamin D supplementation. However, also serum 1,25D increased after correction of low vitamin D status.
- No associations between serum soluble alpha-klotho and baseline vitamin D metabolites were observed.
  - Similarly, after vitamin D supplementation, no associations between serum soluble alpha-klotho and vitamin D metabolites were observed.
- No correlations between serum soluble alpha-klotho concentrations and any other bone metabolism parameters were found.
- Vitamin D supplementation (5000 IU weekly for 15 weeks) did not increase intact FGF-23.
  - Twenty three patients died during 36 months of follow-up. Their baseline serum alpha-klotho concentration did not differ from those who survived on dialysis or were transplanted.

## References

- Haussler MR et al: 1,25-Dihydroxyvitamin D and Klotho: A tale of two renal hormones coming of age. Vitam Horm 2016;100:165
- Hu MC et al: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22:124
- Hu MC et al: Renal and extrarenal actions of klotho. Semin Nephrol 2013;33:118
- Kim HR et al: Circulating alpha-klotho levels in CKD and relationship to progression. Am J Kidney Dis 2013;61:899
- Lau WL et al: Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012;82:1261
- Yokoyama K et al: Serum soluble alpha-klotho in hemodialysis patients. Clin Nephrol 2012;77:347

Study support: Research programe PRVOUK P37/11 and PRVOUK P25/LF1/2 and research projects MH CZ DRO UHHK 00179906 and VFN 64165

Disclosure: none;

e-mail: sylvie.dusilova@fnhk.cz

## Conclusion

Soluble alpha-klotho serum concentrations are independent on vitamin D status in HD patients, both before and after vitamin D supplementation.

Design Jiří Svoboda, www.jsinfo.cz